ENOVIS CORP (ENOV) Stock Fundamental Analysis
NYSE:ENOV - US1940141062 - Common Stock
31.02 USD
-0.15 (-0.48%)
30.85 USD
-0.17 (-0.55%)
ENOV gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 185 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of ENOV have multiple concerns. ENOV has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
ENOV had positive earnings in the past year.
In the past year ENOV had a positive cash flow from operations.
In multiple years ENOV reported negative net income over the last 5 years.
ENOV had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
ENOV's Return On Assets of -16.48% is in line compared to the rest of the industry. ENOV outperforms 51.89% of its industry peers.
The Return On Equity of ENOV (-32.10%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.48% | ||
| ROE | -32.1% | ||
| ROIC | N/A |
ROA(3y)-6.18%
ROA(5y)-3.42%
ROE(3y)-11.19%
ROE(5y)-6.16%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Operating Margin of ENOV has declined.
With a Gross Margin value of 56.32%, ENOV perfoms like the industry average, outperforming 53.51% of the companies in the same industry.
In the last couple of years the Gross Margin of ENOV has grown nicely.
ENOV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.32% |
OM growth 3YN/A
OM growth 5Y-43.59%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y6.07%
2. Health
2.1 Basic Checks
ENOV does not have a ROIC to compare to the WACC, probably because it is not profitable.
ENOV has more shares outstanding than it did 1 year ago.
ENOV has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ENOV is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 0.93, we must say that ENOV is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.93, ENOV is in line with its industry, outperforming 52.43% of the companies in the same industry.
ENOV has a Debt/Equity ratio of 0.53. This is a neutral value indicating ENOV is somewhat dependend on debt financing.
ENOV has a Debt to Equity ratio of 0.53. This is in the lower half of the industry: ENOV underperforms 63.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.93 |
ROIC/WACCN/A
WACC7.44%
2.3 Liquidity
A Current Ratio of 2.25 indicates that ENOV has no problem at all paying its short term obligations.
ENOV has a Current ratio of 2.25. This is comparable to the rest of the industry: ENOV outperforms 42.16% of its industry peers.
A Quick Ratio of 1.15 indicates that ENOV should not have too much problems paying its short term obligations.
ENOV has a worse Quick ratio (1.15) than 70.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.25 | ||
| Quick Ratio | 1.15 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 34.01% over the past year.
ENOV shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -16.18% yearly.
Looking at the last year, ENOV shows a quite strong growth in Revenue. The Revenue has grown by 14.40% in the last year.
Measured over the past years, ENOV shows a decrease in Revenue. The Revenue has been decreasing by -8.73% on average per year.
EPS 1Y (TTM)34.01%
EPS 3Y-23.78%
EPS 5Y-16.18%
EPS Q2Q%27.42%
Revenue 1Y (TTM)14.4%
Revenue growth 3Y13.9%
Revenue growth 5Y-8.73%
Sales Q2Q%7.5%
3.2 Future
Based on estimates for the next years, ENOV will show a very strong growth in Earnings Per Share. The EPS will grow by 23.19% on average per year.
ENOV is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.87% yearly.
EPS Next Y12.61%
EPS Next 2Y11.83%
EPS Next 3Y13.12%
EPS Next 5Y23.19%
Revenue Next Year7.28%
Revenue Next 2Y6.83%
Revenue Next 3Y6.79%
Revenue Next 5Y8.87%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 9.37 indicates a reasonable valuation of ENOV.
ENOV's Price/Earnings ratio is rather cheap when compared to the industry. ENOV is cheaper than 94.05% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.14. ENOV is valued rather cheaply when compared to this.
A Price/Forward Earnings ratio of 8.76 indicates a reasonable valuation of ENOV.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ENOV indicates a rather cheap valuation: ENOV is cheaper than 95.14% of the companies listed in the same industry.
ENOV is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.80, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.37 | ||
| Fwd PE | 8.76 |
4.2 Price Multiples
ENOV's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ENOV is cheaper than 89.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 11.04 |
4.3 Compensation for Growth
ENOV's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ENOV's earnings are expected to grow with 13.12% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.74
PEG (5Y)N/A
EPS Next 2Y11.83%
EPS Next 3Y13.12%
5. Dividend
5.1 Amount
No dividends for ENOV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
31.02
-0.15 (-0.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners106.87%
Inst Owner Change5.05%
Ins Owners1.16%
Ins Owner Change13.88%
Market Cap1.77B
Analysts83.53
Price Target55.42 (78.66%)
Short Float %12.23%
Short Ratio4.49
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.28%
Min EPS beat(2)6.8%
Max EPS beat(2)7.76%
EPS beat(4)4
Avg EPS beat(4)8.94%
Min EPS beat(4)4.97%
Max EPS beat(4)16.23%
EPS beat(8)8
Avg EPS beat(8)5.78%
EPS beat(12)12
Avg EPS beat(12)8.75%
EPS beat(16)15
Avg EPS beat(16)7.78%
Revenue beat(2)0
Avg Revenue beat(2)-1.09%
Min Revenue beat(2)-1.97%
Max Revenue beat(2)-0.21%
Revenue beat(4)0
Avg Revenue beat(4)-1.21%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)-0.21%
Revenue beat(8)2
Avg Revenue beat(8)-0.97%
Revenue beat(12)4
Avg Revenue beat(12)-0.9%
Revenue beat(16)5
Avg Revenue beat(16)-8.66%
PT rev (1m)-7.03%
PT rev (3m)-16.57%
EPS NQ rev (1m)-1.5%
EPS NQ rev (3m)-13.79%
EPS NY rev (1m)2.91%
EPS NY rev (3m)2.06%
Revenue NQ rev (1m)0.64%
Revenue NQ rev (3m)1.6%
Revenue NY rev (1m)0.83%
Revenue NY rev (3m)0.92%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.37 | ||
| Fwd PE | 8.76 | ||
| P/S | 0.81 | ||
| P/FCF | N/A | ||
| P/OCF | 9.43 | ||
| P/B | 0.69 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.04 |
EPS(TTM)3.31
EY10.67%
EPS(NY)3.54
Fwd EY11.41%
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)3.29
OCFY10.61%
SpS38.31
BVpS45.1
TBVpS-9.54
PEG (NY)0.74
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.48% | ||
| ROE | -32.1% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.32% | ||
| FCFM | N/A |
ROA(3y)-6.18%
ROA(5y)-3.42%
ROE(3y)-11.19%
ROE(5y)-6.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5Y-43.59%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y6.07%
F-Score3
Asset Turnover0.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 4.85 | ||
| Cap/Depr | 66.53% | ||
| Cap/Sales | 8.77% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 66.47% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.25 | ||
| Quick Ratio | 1.15 | ||
| Altman-Z | 0.93 |
F-Score3
WACC7.44%
ROIC/WACCN/A
Cap/Depr(3y)55.91%
Cap/Depr(5y)50.8%
Cap/Sales(3y)7.49%
Cap/Sales(5y)6.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.01%
EPS 3Y-23.78%
EPS 5Y-16.18%
EPS Q2Q%27.42%
EPS Next Y12.61%
EPS Next 2Y11.83%
EPS Next 3Y13.12%
EPS Next 5Y23.19%
Revenue 1Y (TTM)14.4%
Revenue growth 3Y13.9%
Revenue growth 5Y-8.73%
Sales Q2Q%7.5%
Revenue Next Year7.28%
Revenue Next 2Y6.83%
Revenue Next 3Y6.79%
Revenue Next 5Y8.87%
EBIT growth 1Y-155.23%
EBIT growth 3YN/A
EBIT growth 5Y-48.51%
EBIT Next Year71.62%
EBIT Next 3Y30.39%
EBIT Next 5Y28.11%
FCF growth 1Y96.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y889.17%
OCF growth 3Y-31.69%
OCF growth 5Y-2.82%